Cancer doctors across the US are running short of essential generic chemotherapy drugs, sparking fear of widespread rationing.

Digoxin therapy may reduce the risk for new-onset or worsening heart failure in patients with symptomatic rheumatic heart disease.

Both non-HDL-C and apolipoprotein B levels independently predict ASCVD risk in patients not receiving statins.

Engaging in moderate to vigorous physical activity concentrated over 1 to 2 days per week may confer survival benefits among adults with OA.

The FDA has approved Tryngolza (olezarsen) to reduce triglycerides and acute pancreatitis risk in adults with severe hypertriglyceridemia (TG ≥500mg/dL).

Right ventricular dysfunction (RVD) is prevalent in 41.7 percent of patients with heart failure with preserved ejection fraction (HFpEF).

A study has determined that adverse effects leading to treatment discontinuation vary among different blood pressure-lowering drug classes.

Men with rheumatoid arthritis have increased odds for heart failure vs women, particularly those with coronary heart disease. Men with rheumatoid arthritis (RA) have higher odds of developing heart ...

Patients with systemic lupus erythematosus (SLE) without lupus nephritis (LN) have increased risk of chronic kidney disease and mortality.

Eosinophilic AE-COPD is associated with a lower risk for major adverse cardiovascular events (MACE) compared with noneosinophilic AE-COPD.

Evolocumab therapy reduces the risk for major cardiovascular events in stable patients with prior percutaneous coronary intervention.

Only 49% of U.S. adults report being “cost secure,” meaning they can pay for the medical visits and treatments they need.